Abivax has been granted a patent for an antitumor pharmaceutical combination involving compound ABX196 and chemotherapeutic or immunotherapeutic agents for cancer treatment. The method includes administering the combination to patients in need. GlobalData’s report on Abivax gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Abivax SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Abivax, Cancer treatment biomarkers was a key innovation area identified from patents. Abivax's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Antitumor pharmaceutical combination for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Abivax SA

A recently granted patent (Publication Number: US11826372B2) discloses a method for treating cancer by administering a therapeutically effective amount of an antitumor pharmaceutical combination free of antigens. The method involves the use of a compound ABX196 of formula (I) in combination with a chemotherapeutic agent such as doxorubicin, cyclophosphamide, or sorafenib. Additionally, the method may include the administration of an immunotherapeutic agent, such as a monoclonal anti-PD1 antibody, specific to a tumor antigen like Her2/neu, EGFR, or VEGF.

Furthermore, the patent claims cover the treatment of various types of cancer, including melanoma, hepatocarcinoma, colorectal cancer, and bladder cancer. The method outlined in the patent aims to provide a comprehensive approach to cancer treatment by combining the antitumor effects of the compound ABX196 with the cytotoxic properties of chemotherapeutic agents and the targeted action of immunotherapeutic agents. This innovative approach holds promise for improving the efficacy of cancer treatment and potentially enhancing patient outcomes in the future.

To know more about GlobalData’s detailed insights on Abivax, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies